 | Up a level |
Journal Article
Holtick, U., Herling, M., Pflug, N., Chakupurakal, G., Leitzke, S., Wolf, D., Hallek, M., Scheid, C. and Chemnitz, J. (2016). Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol containing treosulfan in an elderly population with AML. Bone Marrow Transplant., 51. S. S442 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, Sicre F., Na, I. -K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Grigoleit, G. U., Kuball, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib for corticosteroid-refractory graft-versus-host disease: analysis of 95 patients treated at multiple medical centers. Oncol. Res. Treat., 38. S. 43 - 45. BASEL: KARGER. ISSN 2296-5262
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F. S., Na, I-K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Stoelzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G. U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 29 (10). S. 2062 - 2069. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J. and von Bubnoff, N. (2015). High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers. Bone Marrow Transplant., 50. S. S22 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J. and von Bubnoff, N. (2015). High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers. Bone Marrow Transplant., 50. S. S22 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365